Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04630652

PHASE4

Risankizumab Long-term Remission Study

Sponsor: Jaehwan Kim

View on ClinicalTrials.gov

Summary

Although the newly developed biologics (drugs derived from living cells cultured in a laboratory) are highly effective in controlling psoriasis, all the biologics should be continuously injected to suppress recurrence of the disease. In this regard, the observation in the phase II clinical trial conducted by us (Laboratory for Investigative Dermatology at the Rockefeller University) was groundbreaking that just a single dose of anti-IL-23p19 antibody (risankizumab, trade name: Skyrizi, study drug in this clinical trial) administration produced disease clearance up to 66 weeks in 46% (6 of 13) of patients. However, there is a lack of understanding about immune regulation in human skin induced by anti-IL-23p19 antibody injection, and there is a need to conduct a psoriasis clinical trial for single-cell sequencing immune cells in human psoriasis skin before and after anti-IL-23p19 antibody administration, and to correlate regulatory immune cell alterations with clinical disease progression. The overall objective of the clinical trial is to study regulatory immune cell alterations induced by anti-IL-23p19 antibody administration in psoriasis patients who achieve long-term disease clearance off drugs.

Official title: Immune Modification of Psoriasis by Selective IL-23 Blockade Using Risankizumab

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2021-04-07

Completion Date

2027-07-28

Last Updated

2025-11-03

Healthy Volunteers

Conditions

Psoriasis

Interventions

DRUG

Risankizumab-Rzaa

Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods

PROCEDURE

Punch biopsies of the skin at baseline visit

Two 6 mm punch biopsies of the skin at baseline visit

PROCEDURE

Punch biopsies of the skin at week 28 visit

One 6 mm punch biopsy of the skin at week 28 visit

Inclusion Criteria: * Adult males or females with a diagnosis of plaque psoriasis for at least 6 months. * Baseline Psoriasis Area Severity Index (PASI) score \> 12. * More than 10% body surface area has plaque psoriasis involvement. * Willingness to forgo other available psoriasis therapies, live vaccines, and pregnancy during the trial. * Ability and willingness to provide informed consent and comply with study requirements. Exclusion Criteria: * Non-plaque forms of psoriasis. * Any previous treatment with agents targeting IL-12 or IL-23, including ustekinumab. * Treatment with biologic agents within previous 3 months prior to visit 0, including adalimumab, etanercept, and infliximab. * Treatment with immunosuppressive medications, including methotrexate, cyclosporine, oral retinoids, prednisone, or phototherapy within previous 4 weeks prior to visit 0. * Topical psoriasis treatment within previous 2 weeks prior to visit 0, including topical corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, salicylic acid, and coal tar. * Any investigational study medication within previous 6 months prior to visit 0. * History of recent or ongoing uncontrolled bacterial, viral, fungal, or other opportunistic infections. * Positive QuantiFERON-TB Gold test. PPD tuberculin test may be substituted for QuantiFERON-TB Gold test. * Receipt of a live vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox) in the previous 6 weeks prior to visit 0. * Females who are pregnant, lactating, planning on pregnancy during the study period, or unwilling to use a medically acceptable method of birth control. * Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease, or any other medical condition that, in the investigator's opinion, places the participant at risk by participating in this study. * Any medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results, or any social condition that, in the opinion of the Investigator, might pose additional risk to the participant or confound the results of the study.

Locations (3)

VA Northern California Health Care System

Sacramento, California, United States

University of California Davis Medical Center